260 related articles for article (PubMed ID: 18589402)
41. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.
Marcé S; Molina-Arcas M; Villamor N; Casado FJ; Campo E; Pastor-Anglada M; Colomer D
Haematologica; 2006 Jul; 91(7):895-902. PubMed ID: 16818276
[TBL] [Abstract][Full Text] [Related]
42. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
43. Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1).
Zafar M; Naydenova Z; Coe IR
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):631-642. PubMed ID: 27906634
[TBL] [Abstract][Full Text] [Related]
44. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Wang H; Word BR; Lyn-Cook BD
Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
[TBL] [Abstract][Full Text] [Related]
45. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
47. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
[TBL] [Abstract][Full Text] [Related]
48. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Damaraju VL; Scriver T; Mowles D; Kuzma M; Ryan AJ; Cass CE; Sawyer MB
Clin Cancer Res; 2014 Jan; 20(1):176-86. PubMed ID: 24170548
[TBL] [Abstract][Full Text] [Related]
49. GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Tang Y; Cong X; Wang S; Fang S; Dong X; Yuan Y; Fan J
Biochem Biophys Res Commun; 2018 Sep; 503(4):3142-3148. PubMed ID: 30143259
[TBL] [Abstract][Full Text] [Related]
50. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B; Stacchiotti S; Collini P; Pantano F; Rabitti C; Perrone G; Iuliani M; Baldi A; Badalamenti G; Sanfilippo R; Santini D; Muda AO; Gronchi A; Casali P; Dei Tos AP; Tonini G
Br J Cancer; 2017 Jul; 117(3):340-346. PubMed ID: 28641307
[TBL] [Abstract][Full Text] [Related]
51. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
Jordheim LP; Dumontet C
Biomark Med; 2013 Aug; 7(4):663-71. PubMed ID: 23905902
[TBL] [Abstract][Full Text] [Related]
52. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
53. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
[TBL] [Abstract][Full Text] [Related]
54. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
56. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells.
Hioki M; Shimada T; Yuan T; Nakanishi T; Tajima H; Yamazaki M; Yokono R; Takabayashi M; Sawamoto K; Akashita G; Miyamoto KI; Ohta T; Tamai I; Shimada T; Sai Y
Biopharm Drug Dispos; 2018 May; 39(5):256-264. PubMed ID: 29682747
[TBL] [Abstract][Full Text] [Related]
57. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
58. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
59. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
60. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]